EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically‐based pharmacokinetic modelling

Evangelos Karakitsios, Oscar Della Pasqua iD, Aristides Dokoumetzidis iD

British Journal of Clinical Pharmacology · 2025-11 · 91 (11) · 3167-3178

DOI: 10.1002/bcp.70163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.07.2025. Verfasst von Evangelos Karakitsios und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece. Hauptthemen laut MEDLINE: Diarylquinolines, Antitubercular Agents, Models, Biological, Lung. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking (JU), European Union's Horizon 2020 Research and Innovation Programme, EFPIA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Bedaquiline (BDQ) is a first‐in‐class diarylquinoline (DARQ) and a potent anti‐tuberculosis drug, vital in combating multi‐drug resistant tuberculosis (TB). Understanding its lung pharmacokinetics (PK) across species is crucial for effective clinical translation. This study aimed to extrapolate BDQ’s lung PK from preclinical species to humans, focusing on healthy and TB‐infected lung tissue.

Methods

Physiologically‐based PK (PBPK) modelling was employed to simulate BDQ’s lung distribution in various pulmonary micro‐compartments, including cellular lesions and caseous granulomas, using data from mice, rats and dogs. Complex interactions, such as lysosomal trapping within macrophages and anomalous diffusion within the caseum, utilising a catenary model and a time‐dependent rate, were incorporated into the models to accurately represent BDQ’s unique PK profile.

Results

The study revealed intricate dynamics of BDQ’s lung distribution, with only free concentrations in lysosomes of macrophages surpassing the MIC of Mycobacterium tuberculosis in both mice and humans, indicating intracellular accumulation which may further explain the proven drug’s efficacy. Moreover, during the course of treatment in humans, adequate drug levels were achieved near the cellular rim but penetration into the inner caseous core was predicted to be limited.

Conclusions

Understanding BDQ's lung PK is essential for optimising dosing strategies with new companion drugs. The findings underscore the need to characterise BDQ distribution within the caseum, as it shows extensive caseum binding. Moreover, the developed PBPK model can be applied to new promising DARQ analogues, facilitating their development as effective TB treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiarylquinolinesAntitubercular AgentsModels, BiologicalLungTuberculosis, PulmonaryAnimalsHumansMiceDogsRatsTissue DistributionMycobacterium tuberculosisMaleSpecies SpecificityTuberculosis, Multidrug-ResistantMicrobial Sensitivity TestsFemale

Stichwörter der Autor:innen

bedaquilinedose selectionextrapolationphysiologically‐based pharmacokinetic modellingtissue pharmacokineticstuberculosis

Substanzen

bedaquilineDiarylquinolinesAntitubercular Agents

Autor:innen und Institutionen

  • Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece.
  • Athena Research Center, Pharma-Informatics Unit, Artemidos 6 & Epidavrou, Marousi, Greece.
  • National Research Council (CNR), Rome, Italy.
  • Clinical Pharmacology & Therapeutics Group, University College London, London, UK.

ORCID-Profile: Oscar Della Pasqua, Aristides Dokoumetzidis

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking (JU)
  • European Union's Horizon 2020 Research and Innovation Programme
  • EFPIA
  • Global Alliance for TB Drug Development
  • Bill & Melinda Gates Foundation
  • University of Dundee

Zitieren

APA

Karakitsios, E., Della Pasqua, O., & Dokoumetzidis, A. (2025). Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically‐based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 91(11), 3167-3178. https://doi.org/10.1002/bcp.70163

Vancouver

Karakitsios E, Della Pasqua O, Dokoumetzidis A. Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically‐based pharmacokinetic modelling. British Journal of Clinical Pharmacology. 2025;91(11):3167-3178. doi:10.1002/bcp.70163

BibTeX
@article{Karakitsios2025,
  author = {Karakitsios, Evangelos and Della Pasqua, Oscar and Dokoumetzidis, Aristides},
  title = {Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically‐based pharmacokinetic modelling},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {11},
  pages = {3167--3178},
  doi = {10.1002/bcp.70163}
}
Kostenlos starten →